Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13751772 | 0.92 | MEN1 (0.53) | RAB9ANPC1HTTMAPTMEN1 | |
| SCHEMBL15074523 | 0.86 | RAB9A (0.48) | RAB9ANPC1HTTMAPTMEN1 | |
| SCHEMBL17763406 | 0.83 | MEN1 (0.60) | RAB9ANPC1HTTMAPTMEN1 | |
| SCHEMBL771095 | 0.82 | TSHR (0.59) | RAB9ANPC1LMNAEPHX1TSHR | |
| SCHEMBL21693864 | 0.79 | RAB9A (0.52) | RAB9ANPC1HTTMAPTMEN1 | |
| Nifedipine SCHEMBL20187258 | 0.78 | ADORA3 (0.55) | RAB9ANPC1HTTMAPTMEN1 | |
| SCHEMBL771096 | 0.78 | RAB9A (0.54) | RAB9ANPC1HTTMAPTMEN1 | |
| SCHEMBL11240479 | 0.76 | RAB9A (0.76) | RAB9ANPC1HTTMAPTMEN1 | |
| SCHEMBL31359577 | 0.74 | MAPT (0.64) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL21693865 | 0.73 | MAPT (0.60) | RAB9ANPC1HTTMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240168374-A1 | PHOTORESIST COMPOSITION | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2024-05-23 | — | — | US | claimed |
| US-11623975-B2 | Molding material and method for producing resin molded body using same | OSAKA UNIVERSITY (JP) | 2023-04-11 | — | — | US | claimed |
| US-20260117026-A1 | DIELECTRIC MATERIALS BASED ON HETEROAROMATIC-EXTENDED BISMALEIMIDES | MERCK PATENT GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| EP-4346935-B1 | COATING FOR MEDICAL DEVICES | SMART REACTORS SERVICE LTD (IE) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025083931-A1 | METHOD FOR PRODUCING RESIN MEMBER | 株式会社豊田自動織機 | 2025-04-24 | — | — | WO | disclosed |
| EP-4301804-B1 | DIELECTRIC MATERIALS BASED ON AMIDE-IMIDE-EXTENDED BISMALEIMIDES | MERCK PATENT GMBH (DE) | 2024-12-04 | — | — | EP | disclosed |
| US-20240384332-A1 | PROGRAMMABLE NUCLEASE DIAGNOSTIC DEVICE | MAMMOTH BIOSCIENCES, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240327810-A1 | EFFECTOR PROTEINS AND METHODS OF USE | MAMMOTH BIOSCIENCES, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240294970-A1 | METHODS AND COMPOSITIONS FOR PERFORMING A DETECTION ASSAY | MAMMOTH BIOSCIENCES, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240254262-A1 | DIELECTRIC MATERIALS BASED ON OLIGOAMIDE-EXTENDED BISMALEIMIDES | MERCK PATENT GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
| US-20240226395-A1 | COATING FOR MEDICAL DEVICES | Smart Reactors Service Limited (IE) | 2024-07-11 | — | — | US | disclosed |
| US-8236476-B2 | Multiple exposure photolithography methods and photoresist compositions | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120176456-A1 | ULTRAVIOLET CROSSLINKING INK AND INKJET RECORDING METHOD | RICOH COMPANY, LTD., (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120178027-A1 | MULTIPLE EXPOSURE PHOTOLITHOGRAPHY METHODS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178027-A1 | MULTIPLE EXPOSURE PHOTOLITHOGRAPHY METHODS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2009087029-A1 | MULTIPLE EXPOSURE PHOTOLITHOGRAPHY METHODS AND PHOTORESIST COMPOSITIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176174-A1 | MULTIPLE EXPOSURE PHOTOLITHOGRAPHY METHODS AND PHOTORESIST COMPOSTIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176174-A1 | MULTIPLE EXPOSURE PHOTOLITHOGRAPHY METHODS AND PHOTORESIST COMPOSTIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2009-07-09 | — | — | US | disclosed |
| US-7341775-B2 | Composition for forming porous film, porous film and method for forming the same, interlevel insulator film, and semiconductor device | MATSUSHITA ELECTRIC INDUSTRIAL CO. LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-7341775-B2 | Composition for forming porous film, porous film and method for forming the same, interlevel insulator film, and semiconductor device | MATSUSHITA ELECTRIC INDUSTRIAL CO. LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254262-A1 | DIELECTRIC MATERIALS BASED ON OLIGOAMIDE-EXTENDED BISMALEIMIDES | GNE, SMCHD1, KCNE1 | RAB9A 3665/4885NPC1 4879/4885HTT 2959/4885 |
| US-20260117026-A1 | DIELECTRIC MATERIALS BASED ON HETEROAROMATIC-EXTENDED BISMALEIMIDES | KCNE1, GLRB, PBRM1 | RAB9A 2755/4885NPC1 4814/4885HTT 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.